For non-small cell lung cancer cells (NSCLC), chelidonine (22) has strong inhibitory effects, which are achieved primarily through the ability to selectively inhibit the EGFR phosphorylation and inhibit mitochondrial function in EGFR double mutant cells. Here, EGFR is linked to non-small cell lung carcinoma.